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Objective:
 
 The primary objective of this study was to
assess the appropriateness of the existing Dutch clinical
 
guidelines for the treatment of depression from a health-
 
economic perspective. The existing guidelines recommend
continuation treatment for a period up to 9 months.
 
Methods:
 
 The assessment was based on a Markov model
using decision-analytic techniques. For this analysis we
defined six mutually exclusive states defined by the exist-
ence of depression and type of treatment. The outcomes
for the model were defined as: time without depression
(TWD), quality-adjusted life years (QALYs), direct medi-
cal costs, and cost of lost productivity. The primary per-
spective of the study was that of the third-party payer,
while the secondary perspective was that of the society in
1999. The probabilities of clinical events and therapeutic
choices as well as the utilities were based on published
literature. The medical resource use related to each state
was abstracted from published literature and expert
opinion. The associated 1999 unit costs of the used med-
ical resources were derived from official Dutch tariff lists
of allowable reimbursements. Indirect costs in this model
were based on lost productivity only.
 
Results:
 
 The results of the primary analysis showed that
the use of the guidelines is not cost-effective. Continua-
tion treatment for a period of 9 months increases the
total direct medical costs (NLG 1276 vs. NLG 474), de-
creases the costs resulting from lost productivity (NLG
304 vs. NLG 909), increases total costs (NLG 1580 vs.
NLG 1383) and increases TWD (96.9% vs. 86.4%).
However, continuation treatment does not change the
utility outcomes (0.60 vs. 0.61 QALYs) for both treat-
ment strategies. Hence continuation treatment is not
cost-effective from either a third-party payer perspec-
tive or a societal perspective. A scenario analysis showed
that an extension of the continuation treatment to main-
tenance treatment might result in a favorable cost-effec-
tiveness outcome of the treatment guideline.
 
Conclusion:
 
 In conclusion, based on the assumptions
used in the model, the current Dutch treatment guide-
lines for depression are only appropriate from a health-
economic perspective if continuation treatment is ex-
tended to maintenance treatment.
 
Keywords:
 
 cost benefit, depression, Dutch clinical guide-
lines, treatment continuation.
 
Introduction
 
Epidemiology
 
Depression is a common debilitating illness that
has a great social, medical, and economic effect on
society. Epidemiological studies show a prevalence
varying between 1% and 4% in women and be-
tween 2% and 3% in men [1–3]. The highest prev-
alence of the disease appears to be in adults be-
tween the ages of 18 and 44 [4,5]. A study by
Ormel yields a prevalence of 6.7% for persons
older than 18 years in the Netherlands, which is
the study country in this manuscript [6].
 
Economic Impact of Depression
 
Although there is some variation due to the diver-
sity of health care systems, as a rule of thumb
most of the developed countries spend about 10%
of their national income on health care [7]. About
10% of total health care expenditure is spent on
the treatment of mental disorders [8]. Several im-
portant findings have emerged with regard to men-
tal disorders. Most recent studies point out that the
economic burden of depression consists of health
care expenditures (direct costs) and costs related
to loss of productivity [9,10]. There are a number
of other factors that may explain why depression
is such a significant problem of public health,
leading to long-term morbidity and costs: 1) de-
pression has a high risk of recurrence and chronic-
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ity; 2) the fact that depression is mainly prevalent
among young adults (between 18 and 44 years)
means that the patients involved represent the ac-
tive population, increasing the costs to society
through productivity losses from work days lost
[3]; 3) severe depression can lead to frequent and
lengthy hospitalizations, which have an enormous
impact in economic terms [11]; and 4) major de-
pression is associated with significant social mor-
bidity and decreases in health status and well being,
and impacts dramatically the ability of patients to
function normally in the work place [12–14].
 
Treatment of Depression
 
The drugs most often used in current treatment
patterns for depression include the tricyclic antide-
pressants (TCAs) and the newer selective serotonin
reuptake inhibitors (SSRIs), which are associated
with fewer side effects [15,16]. Depressive episodes
usually respond well to short-term treatment; stud-
ies have shown that approximately 65% to 80%
of depressive patients can be treated effectively
with antidepressant drugs, while placebo response
rates have often been in the range of 20% to 40%
[17]. The treatment of the acutely depressed pa-
tient is referred to as short-term or episodic treat-
ment. Although patients usually respond well to
short-term treatment, relapse and recurrence are
common problems in clinical practice [18–20]. A
new episode may be either a relapse or a recur-
rence, which are now recognized as two distinct
events, the former being a re-emergence of the
original depressive and the latter the emergence of
a new episode, unrelated to the original [18]. A re-
lapse has been loosely defined as a depressive event
that takes place within 4 to 6 months of the origi-
nal event, whereas a recurrence occurs after this
period [15]. Patients who achieve a stable asymp-
tomatic state with full restoration of psychosocial
function and who are symptom free for 6 months
or more following an episode of depression are
said to have recovered [21,22]. A review of studies
with a follow-up of more than 1 year has shown
consistently high rates of recurrence; all patients
experienced at least two episodes in Perris’ and
Angst’s study, and 96% in Carlson’s and 78% in
Lehman’s studies, respectively [23–26]. Studies in-
dicate that 50% to 85% of patients with a diagno-
sis of major depression will experience at least one
more episode of depression in their lifetime [27,28],
and individuals with a history of two or more de-
pressive episodes have almost a 90% chance of ex-
periencing a third [29].
 
Several studies have indicated that long-term
treatment of depression may be beneficial for pa-
tients with major depression [30–32]. The findings
of those studies resulted in recommendations for
prolongation of antidepressant medication. Accord-
ingly, the WHO (World Health Organization Men-
tal Health Collaborating Centers, 1989) [33], the
Agency for Health Care Policy and Research
(AHCPR) [34] in the United States, and numerous
other consensus groups (Paykel and Priest [35],
Montgomery et al., 1993 [36], American Psychiat-
ric Association [37], Commission de Transparence,
1994 [38], Swedish Board of Health [39]) have es-
tablished depression treatment guidelines recom-
mending at least 4 to 9 months of antidepressant
therapy beyond initial symptom resolution for an
initial depressive episode, with longer antidepres-
sant treatment for subsequent episodes. The clinical
treatment guidelines for Dutch GPs (NHG standard
guideline by the Dutch Association of GPs “Neder-
lands Huisartsgenootschap”) recommend a period
of continuation treatment up to 9 months after an
initial response to medication [40].
As mentioned above, a distinction should be
made between relapse and recurrence. The deci-
sion whether to continue treatment after a positive
response and for how long should therefore take
into consideration both the risk of relapse and the
risk of recurrence. Hence, prolongation treatment
may be considered to consist of two components,
one aimed at preventing a relapse, and one aimed
at preventing recurrence. Those components have
been labeled continuation and maintenance treat-
ments, respectively, and for the rest of this article
we will use this terminology.
Although the clinical efficacy of the SSRIs is
comparable to that of the TCAs [41], their major
advantage in clinical practice is the lower inci-
dence of side effects and increased patient compli-
ance [15,42,43]. The use of antidepressive medica-
tion in the Netherlands has been studied using a
local database of GPs over the period 1994 to
1995. This study showed that nearly all patients
using SSRIs received the minimal effective dosage
versus only 61% of the patients using TCAs [44].
Hence the increased patient tolerability of SSRIs
clearly makes them ideal agents for the long-term
maintenance phase of treatment, which has been
confirmed by a number of studies [20,32,45,46].
In those studies, responders to an acute treatment
with an SSRI were randomized to prolongation of
the treatment or switched to placebo, and relapse
and/or recurrence were assessed during the contin-
uation and/or maintenance periods.
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Assessment of Clinical Guidelines from a 
Health-economic Perspective
 
A growing number of organizations have issued
clinical guidelines for prolongation of antidepres-
sant medication following response to an initial
antidepressant medication [34–36,38–40,47]. Clin-
ical guidelines outline the proper care of medical
conditions and the performance of clinical proce-
dures. The intended goal of guidelines is to reduce
inappropriate care and to improve patient out-
comes. In addition, these guidelines are potential
tools for reducing the costs of health care and for
improving medical education [48]. While the prin-
cipal goal of clinical guidelines is to define what is
best for the individual patient, an assessment of
such guidelines from a health-economic perspec-
tive is performed from the broader societal per-
spective. This approach consists of relating cumu-
lative measures of costs over time to cumulative
measure of clinical benefit. Economic measures such
as direct medical costs and cost of lost productiv-
ity must be considered, while costs play a minor
role in the decision making for clinical guidelines
[49,50]. Another difference is that the majority of
clinical guidelines have been based on efficacy out-
comes of randomized clinical trials—relapse and
recurrence rates for continuation and maintenance
treatment, respectively. Ideally, health-economic
studies should not be based on efficacy, but on ef-
fectiveness in terms of morbidity and mortality
(e.g., quality-adjusted life years [QALYs]). If no
effectiveness data are available, then appropriate
modeling techniques may be used to model effi-
cacy data into what is expected in practice (effec-
tiveness). All assumptions behind such modeling
techniques should be supported by sensitivity anal-
ysis.
Economic evaluation is a valuable tool allowing
strategic choices to be made in the context of
health care policy. This approach appears to be
particularly relevant in terms of chronic disorders
that are common and make use of many health
care resources. A health-economic assessment of
clinical guidelines is especially relevant when the
disease leads to a high burden on society in terms
of costs and social morbidity (quality of life). Con-
sequently the necessity for a health-economic as-
sessment of clinical guidelines may be based on
the following criteria: 1) prevalence or incidence;
and 2) cost of illness. According to both criteria
and considering the epidemiological and economic
data presented on depression, it is obvious that a
health-economic assessment of clinical guidelines
for treatment of depression is justified.
The primary objective of this cost-effectiveness
study was to determine the appropriateness of the
Dutch “NHG-standard” recommending continua-
tion of treatment from a health-economic perspec-
tive; a secondary objective was to determine the
optimal period of prolongation of an antidepres-
sant medication.
The underlying hypothesis of this study was that
a prolongation of an antidepressant treatment will
lead to a favorable health-economic outcome com-
pared with short-term treatment only. A reduction
of relapse and/or recurrence will result in: 1) an in-
crease in time without depression (TWD), in qual-
ity of life, and consequently, in QALYs; and 2) a
reduction of total costs (direct medical costs and
costs of lost productivity), which will lead to a fa-
vorable incremental cost-effectiveness outcome.
 
Methods
 
Analytical-decision techniques were used to spec-
ify the potential health-economic benefits of the
clinical guidelines. This application of analytical-
decision techniques to the development of guidelines
is relatively new, and thus there is limited experience
[51,52]. In that sense, this study is exploratory
in nature. Its main aim is to show how health-
economic analysis can be used alongside clinical
guideline development. This cost-effectiveness anal-
ysis compared prolongation of antidepressant med-
ication versus no prolongation after response to an
initial treatment with an antidepressant in the Dutch
health care setting. The Netherlands was chosen for
the purpose of illustration because this country was
the first European country to have developed phar-
macoeconomic research guidelines [53]. Hence, this
offered the opportunity of conducting a health-eco-
nomic analysis according to these standardized re-
search guidelines. The primary perspective of the
study was that of the third-party payer, while the
secondary perspective was that of the society in
1999.
 
Markov Models
 
Health-economic modeling studies are based on
decision analysis, which allows for the analysis of
both clinical and economic consequences of medi-
cal actions and attitude [54]. A model can be con-
structed from treatment algorithms, which include
the timing of actions and their consequences over
time. It allows for the evaluation of the conse-
quences and complications associated with differ-
ent therapeutic interventions and should corre-
spond as much as possible to the presentation of
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the disease in a clinical setting. Models may take
the form of simple decision-analytic trees or they
may be very complex Markov models. Whereas
decision-tree models are appropriate for acute ill-
nesses, Markov models are the first choice for
pharmacoeconomic analysis of chronic diseases like
depression. The data used in a modeling study can
be categorized into transition probabilities (e.g.,
response, relapse, and recurrence), health care uti-
lization (e.g., drugs, consultations), prices and tar-
iffs, and utilities [55]. The data may come from a
variety of sources and is subject to varying degrees
of uncertainty. Data for the variables being used
in a model may be taken from clinical trials, litera-
ture (e.g., meta-analysis), databases, medical records,
and official tariff lists of allowable reimburse-
ments. These data sources yield a fixed input value
(usually the average of the relevant data found)
and a range (determined by the variation of the
data values) for each variable. The standard anal-
ysis is based on the fixed input value for all vari-
ables. The range of each variable is then used to
determine the sensitivity of the outcome of the
analysis when the input value is varied within its
range.
 
Description of the Markov Model
 
A Markov process represents a convenient way of
modeling the long-term evolution of health states
over successive time periods [56]. A Markov pro-
cess model describes several discrete states of
health in which a person can be at time t 
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 1 is called a cycle. Probabil-
ities are associated with each change from one
health state to another; these are termed transition
probabilities (
 
p
 
). Each transition probability is a
function of the state of health and of the time
spent in each health state. The Markov model
used in this study is shown in Figure 1; each
Markov state is assigned a utility, and the overall
contribution of this utility depends on the length
of time spent in the state. A utility can be a clinical
as well as an economic parameter.
For this analysis we defined six mutually exclu-
sive states based on the existence of depression
and the type of treatment applied:
1. no depression and no prolongation of treatment
(ND);
2. no depression and prolongation with SSRI (ND-
SSRI);
3. no depression and prolongation with TCA (ND-
TCA);
4. depression in ambulatory setting treated with
SSRI (AD-SSRI);
5. depression in ambulatory setting treated with
TCA (AD-TCA); and
6. treatment failure in severe depression requiring
hospitalization (DH).
Patient progression through these states was di-
vided into cycles of 2 months. A 2-month cycle
time was chosen because this interval closely ap-
proximates the time of the sequential therapeutic
stages: e.g., the initial 2-month trial of antidepres-
sant medication is followed by a continuation
treatment for another 6 months in case the patient
responded positively.
 
Description of the Transitions
 
In the model all patients begin in the state identi-
fied above as “no depression,” either with or with-
out medication, and during each subsequent cycle
they either remain in the same state or progress to
another state, depending on the allowed transi-
tions and their associated probabilities. The tran-
sition probabilities between the states are based
on relapse and recurrence rates for responders
with or without prolonged treatment and subse-
quent response rates to treatment. The model is
based on the following assumptions:
Figure 1 Markov states and possible transition used in the model.
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No Prolongation and Prolongation of Treatment:
 
• The low patient compliance with TCAs makes
them less than ideal for prolongation treat-
ment. Therefore the health-economic assess-
ment was based on prolongation of first-line
treatment for depression with an SSRI.
• A patient will be hospitalized after three subse-
quent treatment failures or dosage increases of
antidepressants.
• An increase in dose of antidepressant medica-
tion (SSRI or TCA) was not included in our
model. The assumption is that an increase in
dose of antidepressant medication will occur
within the cycle time of 2 months.
• We have excluded the possibility of suicide in
the model. Although patients with depression
may have a significant risk for suicide over the
long-term, previous studies showed that the inci-
dence of suicide over a period of 18 months was
negligible, being less than 1% [57]. For the same
reason, suicide was not included in a previous
publication by our group nor was it included in
the study by Jonsson, as the cost associated with
suicide is minimal due to the low incidence and
the relatively low impact on cost [58,59].
 
No Prolongation of Treatment:
 
• Patients not currently on prolongation treat-
ment will be treated again with an SSRI after a
relapse or recurrence. In the event of no re-
sponse to this treatment, the patient will be
switched to a TCA.
• Patients who do not respond to a TCA will be
switched to another type (class) of TCA.
• Responders to a SSRI or a TCA will discon-
tinue this treatment after the short-term treat-
ment period.
 
Prolongation of Treatment:
 
• Patients receiving prolonged treatment with a
SSRI who experience a relapse or recurrence
will be switched to a TCA. The probability of a
response will correspond to the probability of
response to first-line antidepressant treatment.
• Responders to a SSRI will continue this treat-
ment as prolongation treatment after the short-
term period.
• Responders to a TCA will, in the base-case
analysis, terminate this treatment for the pur-
pose of prolongation treatment after the short-
term period because of the low level of compli-
ance with TCAs; in a scenario analysis, they
will continue this treatment according to the
Dutch clinical guidelines.
• Patients who do not respond to a TCA will be
switched to another type (class) of TCA.
• Patients who experience a relapse or recurrence
after termination of an antidepressant treatment
consist of two subpopulations: 1) patients who
would have experienced a relapse or recurrence
on prolonged treatment; and 2) patients who
would not have experienced a relapse or recur-
rence on prolonged treatment. Both groups of
patients will be treated with the initial antide-
pressant that resulted in the response. The first
group of patients will not respond to this medi-
cation; the second group of patients will have a
probability of response corresponding to an ini-
tial antidepressant treatment.
• Patients receiving prolonged treatment with
the first TCA who experience a relapse or re-
currence will be switched to another TCA. The
probability of a response will correspond to
the probability of response to a first-line anti-
depressant treatment. Patients receiving pro-
longed treatment with the second class of TCA
who experience a relapse or recurrence will be
hospitalized.
 
Clinical and Economic Outcomes
 
The clinical outcomes for this model were identi-
fied as being TWD and QALYs; the economic out-
comes were the direct medical costs and costs
resulting from lost productivity. The primary per-
spective of the study was that of the third-party
payer, while the secondary perspective was that of
the society in 1999. From a scientific point of view,
the societal perspective should include all indirect
costs, including the costs of time spent. However,
the Dutch pharmacoeconomic research guidelines
state that “the focus is on production losses, when
including indirect costs” [53]. The costs were de-
termined from the perspective of the Dutch society
in 1999, and utilities and costs were discounted at
4% accordingly.
The cost assessment was based on the assign-
ment of costs to defined health states associated
with a cycle time of 2 months. The direct medical
cost of each health state was determined by the
health care utilization associated with each health
state, including medication, consultations, proce-
dures, tests, and number of days of hospitalization.
The cost resulting from lost productivity was based
on working days lost over a period of 2 months.
 
Data Sources
 
Different types of data can be distinguished in
modeling studies:
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• probability of clinical events, generally beyond
the control of the physician (e.g., probability
of relapse, recurrence, and response);
• probability of therapeutic choices (e.g., ther-
apy after a relapse or during continuation or
maintenance treatment;
• utilities of different Markov health states; and
• direct medical costs, consisting of the units of
health care utilization and their prices/tariffs.
Costing of direct medical costs involves esti-
mating the number of units of health care utili-
zation and multiplying this by the correspond-
ing price/tariff. Costing for lost productivity
involves estimating the number of workdays
lost and the opportunity cost to society.
The probability of clinical events and therapeu-
tic choices was based on published literature (Table
1). The response to first- and second-line antide-
pressant medication was derived from a study by
Nuijten [59]. The percentage of patients relapsing
during continuation treatment with an SSRI was
based on the average of the percentage of patients
relapsing in two randomized, double-blind, clinical
trials by Montgomery and Dunbar [32] and Mont-
gomery and Rasmussen [45]. The percentage of
patients not on continuation treatment who relapsed
was based on the percentage of patients receiving
placebo who relapsed in those clinical studies.
 
The percentage of recurrence during mainte-
nance treatment with an SSRI was based on the
percentage of recurrence in the two clinical studies
published by Montgomery in 1988 [46] and 1993
[32]. The percentage of recurrence among patients
not on maintenance treatment was based on the
percentage of recurrence among placebo-treated
patients in these clinical studies. The relapse rate
for patients treated with TCAs was derived from a
literature review by Nuijten [57] which was based
on data from various trials [60–62].
The Actuarial Method was used to adjust all re-
lapse and recurrence percentages to transition prob-
abilities corresponding to a cycle time of 2 months
[63]. It was remarkable that the transition proba-
bilities for relapse and recurrence for patients on
placebo were similar in both studies.
The utilities for the different health states were
derived from a study by Revicki (Table 2) [64]. All
utilities were determined for ambulatory treat-
ment. We assumed that the utility for the health
state corresponding to hospitalization was equiva-
lent to the utility for severe depression, an as-
sumption that was validated by expert opinion
(DA Revicki, MEDTAP International, Bethesda,
Washington, USA).
Medical resource use for each health state was
abstracted from published literature (Table 3) [65].
The treatment patterns and resource utilization
 
Table 1
 
Clinical data and sources
 
Clinical data Transition probability Reference
SSRI
Response to first-line treatment 0.600 [59]
Response to second-line treatment 0.300 [59]
Relapse during continuation treatment 0.016 [32]
0.040 [45]
Mean 0.028
Recurrence during maintenance treatment 0.036 [32]
0.049 [46]
Mean 0.042
TCA
Relapse during continuation treatment 0.092 [57]
Recurrence during maintenance treatment 0.018 [74]
Relapse after termination 0.112 [32]
0.100 [45]
Mean 0.106
Recurrence after termination 0.084 [32]
0.131 [46]
Mean 0.108
Response to hospitalization
TCA 0.581 [66]
SSRI 0.643 [66]
TCA 0.612 [67]
SSRI 0.627 [68]
Mean 0.616
 
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
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were adjusted to 1999 values and validated by
expert opinion. The associated 1999 unit costs of
medical resources used (e.g., professional services,
health care services, facilities and tests conducted)
were derived from official Dutch tariff lists of al-
lowable reimbursements (Taxe; November 1999.
Koninklijke Maatschappi; ter Bevordering der Phar-
macie. The Hague. The Netherlands. 1999.) and
other sources CTG (College Taríeven Gezond-
heidszorg): central tariffs in health care for consul-
tations and procedures, Utrecht, The Netherlands.
1999. The daily treatment cost (DTC) with an
SSRI was an average of the DTCs of the four most
prescribed SSRIs in the Netherlands (IMS). Dos-
ages of drugs were derived directly from the offi-
cial Dutch formulary (Farmacotherapeutisch Kom-
pas) (Table 3). The base-case analysis was based
on the cheapest TCA, amytriptiline.
Costs resulting from lost productivity in this
model were based on the value of working days
lost, according to the gross domestic product (GDP)
per-capita figure. Because lost productivity is fre-
quently excluded from pharmacoeconomic analy-
ses, it was difficult to find data directly applicable
to the Netherlands for this study, and so we used
data from the study by Broadhead et al. [14]. We
assumed that lost productivity for depressed pa-
tients is consistent, whether they are treated with
an SSRI or with a TCA. When the results of this
study were adjusted to our cycle time of 2 months,
depression was found to increase the number
working days lost to 5.8 over a period of 2
months. The cost of lost productivity resulting
from hospitalization was calculated by assuming
100% productivity losses. Assessment of lost pro-
ductivity was based on the friction method; the
Dutch pharmacoeconomic research guidelines rec-
ommend the use of the Friction Cost Method over
the more traditional Human Capital Approach
(HCA) [53]. The use of an appropriate method of
assessment is especially relevant for chronic dis-
eases like depression, where the use of HCA would
have lead to an overestimation of the cost of lost
productivity.
Sensitivity analyses were performed on the rele-
vant variables in our model. Sensitivity analyses
were performed on relapse and recurrence proba-
bilities under prolongation treatment because both
figures were derived from a limited number of
clinical trials with limited external validity. The
response rate to hospitalization was based on the
average of the response rates reported in studies
that assessed the efficacy of intramural adminis-
tration of antidepressants [66–68]. The lower and
upper ranges were based on the minimum and
maximum values that we found in the literature
(Table 1). In addition, we performed sensitivity
analyses on the DTC of a TCA and the per diem.
The DTC for TCA was varied between minimum
and maximum values; the per diem was varied be-
tween plus and minus 10%.
Sensitivity analysis is based on the modification
of the basic clinical and economic estimates of in-
put variables over a plausible range to evaluate the
effect on study results of alternative assumptions
for uncertain variables [69]. In contrast, scenario
analysis is based on the modification of the under-
lying therapeutic strategies of the model. In this
study, a scenario analysis was performed on the
prolongation of a treatment with a TCA assuming
full compliance. Another scenario analysis was
performed on an extension of the continuation treat-
ment as recommended by the guidelines to an extra
year of maintenance treatment. Finally a scenario
analysis was performed on compliance during pro-
longed antidepressant treatment with an SSRI.
 
Results
 
The Markov model was built using the decision-
tree software (DATA 3.5, TreeAge Software, Will-
 
Table 2
 
Utilities for health states
 
Health state
Utility
Fixed input value
Treatment depression: SSRI 0.70
Treatment depression: TCA 0.64
In remission SSRI, prolongation 0.80
In remission TCA, prolongation 0.72
In remission, off drug therapy 0.86
Severe depression 0.30
 
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
 
Table 3
 
Cost data and sources
 
Direct costs (NLG) Costs* Range Reference
SSRIs 2.60 Taxe, Nov. 1999
TCA: amytriptiline 0.25 Taxe, Nov. 1999
TCA: anafranil, 
clomipramine
0.94
Consultation 40.00 COTG ’99
Per diem 289.00 280–295 COTG ’99
Cost of lost productivity Reference
Working days lost 
 

 
2 
months 5.2 Broadhead
GDP per capita (NLG) 42729 CBS, 1999
GDP per capita per 
working day 244 CBS, 1999
 
*daily treatment costs for drugs. SSRI, selective serotonin reuptake inhibitor;
TCA, tricyclic antidepressant.
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iamstown, MA, 1996). The model was run to give
an expected value for TWD, QALYs and cost per
patient. Sensitivity analyses were performed on the
main clinical and economic input variables in or-
der to ascertain the robustness of the conclusions,
and additional scenario analyses were performed.
The key results of the analysis are shown in Ta-
ble 4, and show that the use of guidelines (prolon-
gation treatment) increases the total direct medical
costs substantially from NLG 474 to NLG 1276,
while it reduces the cost of lost productivity sub-
stantially from NLG 909 to NLG 304. The use of
the guideline increases TWD substantially from
86.4% to 96.9%, while it does not increase the
number of QALYs (0.60 vs. 0.61). This first incre-
mental cost-effectiveness analysis (cost/QALY) shows
that the use of the guidelines is not cost-effective,
either from the third-party payer perspective (medi-
cal costs) or from the societal perspective; termination
of treatment is dominant versus prolongation be-
cause prolongation increases the costs without an
increase in QALYs. The results of the incremental
cost-effectiveness analysis on TWD are expressed
in extra costs per extra month without symptoms
of depression; the results vary from NLG 854 to
NLG 210 for the third-party payer and the soci-
etal perspectives, respectively.
Prolonged treatment until 21 months (continu-
ation treatment followed by maintenance treat-
ment) reduces the medical costs from NLG 4681
to NLG 3831 when compared with termination of
treatment. Maintenance treatment increases TWD
from 82.9% to 94.9%, while it does not increase
the number of QALYs (1.31). Hence, maintenance
treatment is cost-effective from both the third-
party payer and the societal perspectives because
prolongation decreases the costs without a de-
crease in QALYs.
Table 5 provides a breakdown of direct costs
by components: drugs, consultations, and hospi-
talizations. As would be expected, the costs of
drug therapy and associated extra consultations
were higher for prolongation treatment, whereas
the cost of hospitalizations is lower due to fewer
relapses. Only an extension to a maintenance treat-
ment is cost saving, since the higher drug and con-
sultation costs are offset by the reduction in hospi-
talization costs.
Table 6 and Table 7 show the results of the sce-
nario analysis, which assumes that treatment with
TCAs will be continued after a response. The analy-
sis shows that the 9-month results are still similar to
the base-case analysis. Prolonged treatment until 21
months (continuation treatment followed by main-
tenance treatment) reduces the total costs slightly
more than the base-case analysis (NLG 3747 vs.
NLG 3620). Table 7 shows that cost savings result
 
Table 4
 
Discontinuation of TCAs
 
Outcome
Costs (NLG) Time without depression QALY
Direct Lost productivity Total costs % Months Years
Base case: 9 months
Prolongation 1276 304 1580 96.9 8.72 0.60
Termination 474 909 1383 86.4 7.78 0.61
Difference 803
 

 
606 197 10.4 0.94
 

 
0.01
ICR (Cost/month) 854 210
ICR (Cost/QALY) TD TD
Scenario: 21months*
Prolongation 3831 1512 5343 94.9 17.09 1.31
Termination 4681 4282 8963 82.9 14.92 1.31
Difference
 

 
850
 

 
2770
 

 
3620 12.0 2.17 0.00
ICR (Cost/month) PD PD
ICR (Cost/QALY) PD PD
 
*Discounting at 4%. QALY, quality-adjusted life years; ICR, incremental cost-effectiveness ratio; TD, termination dominant; PD, prolongation dominant.
 
Table 5
 
Cost distribution of direct medical costs: 
discontinuation of TCAs
 
Outcome
Costs (NLG)
Drugs Consultations Hospitalization Total
Base case: 9 months
Prolongation 736 309 232 1276
Termination 75 53 346 474
Difference 661 255
 

 
114 803
Scenario: 21months*
Prolongation 1514 642 1675 3831
Termination 178 129 4374 4681
Difference 1336 513
 

 
2698
 

 
850
 
*Discounting at 4%. TCAs, tricyclic antidepressants.
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from a further reduction in hospitalization costs
(savings of NLG 2775 vs. NLG 2698). As would be
expected, continuation of TCA treatment will lead
to higher costs for drug therapy and associated ex-
tra consultations compared with discontinuation,
but continuation will also reduce relapses and recur-
rences in responders to TCAs, which will lead to
further reductions in hospitalizations and lost pro-
ductivity and an increase in TWD. On the other
hand, continuation with TCAs will not lead to a
higher number of QALYs: Table 2 shows that the
unfavorable side effect profile of TCAs is associated
with lower QALYs for patients using TCAs either
for acute treatment or prolongation treatment.
Table 8 and Table 9 show the results of the sen-
sitivity analyses for the base-case analysis (9-month
treatment) and the scenario analysis (maintenance
treatment), respectively. The sensitivity analyses
for the base-case analysis show that modifying the
variables within their range does not change the
outcome of our model, whereas sensitivity analy-
ses for maintenance treatment show that the out-
come of our model is not sensitive to most of the
variables other than the relapse rate during pro-
longation of treatment. When the analysis is based
on the maximum values, termination of treatment
becomes more favorable than maintenance treat-
ment.
Tables 10 and 11 show the relationship be-
tween the expected outcomes and compliance with
SSRI treatment when TCAs are discontinued after
a response (base-case analysis) and compliance is
varied between 20% and 80%. These results show
that lower compliance substantially reduces poten-
tial cost savings of prolongation treatment, especially
in the maintenance-treatment scenario. Although
compliance does not have an impact on QALYs,
lower compliance substantially reduces TWD.
 
Discussion
 
This study examines the cost-effectiveness of con-
tinuation treatment with SSRIs compared to no
preventive treatment in order to assess the appro-
priateness of clinical guidelines for continuation
treatment. In our model, the use of the NHG guide-
line recommending a continuation treatment for 9
months was not cost-effective, when compared to
no prolongation, in responders to an initial treat-
ment. A scenario analysis revealed that only con-
tinuation of treatment followed by maintenance
treatment with SSRIs was favorable, both in terms
of cost and effect, in the treatment of patients with
depressive disorders in a Dutch setting. This sce-
nario analysis showed that an extension of the
continuation treatment will decrease the medical
costs and the costs of lost productivity compared
with no prolonged treatment, while it will increase
the TWD. Sensitivity analyses showed the robust-
ness of our conclusion. Although continuation of
 
Table 6
 
Costs associated with continuation of TCAs
 
Outcome
Costs (NLG) Time without depression QALY
Direct Lost productivity Total % Months Years
Base case: 9 months
Prolongation 1278 302 1580 96.9 8.72 0.59
Termination 474 909 1383 86.4 7.78 0.61
Difference 804
 

 
607 197 10.5 0.94
 

 
0.02
ICR (Cost/month) 852 209
ICR (Cost/QALY) TD* TD
Scenario: 21 months*
Prolongation 3801 1415 5216 95.2 17.13 1.27
Termination 4681 4282 8963 82.9 14.92 1.31
Difference
 

 
880
 

 
2867
 

 
3747 12.3 2.22
 

 
0.04
ICR (Cost/month) PD* PD
ICR (Cost/QALY) TD TD
 
*Discounting at 4%. QALY, quality-adjusted life years; ICR, incremental cost-effectiveness ratio; TD, termination dominant; PD, prolongation dominant.
 
Table 7
 
Cost distribution of direct medical costs: 
continuation of TCAs
 
Outcome
Costs (NLG)
Drugs Consultations Hospitalization Total
Base case: 9 months
Prolongation 736 309 232 1276
Termination 75 53 346 474
Difference 662 256
 

 
114 803
Scenario: 21 months*
Prolongation 1539 663 1599 3801
Termination 178 129 4374 4681
Difference 1361 534
 

 
2775
 

 
880
 
*Discounting at 4%.
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TCA treatment will lead to cost savings, the use of
TCAs will have a negative impact on QALYs due
to their unfavorable side-effect profile. In addi-
tion, published data show that compliance with
TCAs is low in real practice, which justifies our
base-case analysis in which only continuation with
SSRIs is considered [44].
Although the use of the guideline increases
TWD substantially, it does not increase the QALYs.
The values for utilities (Table 2) explain this out-
come: the use of an antidepressant reduces the
QALYs of health states in patients without depres-
sion because of side effects. Although prolonga-
tion treatment reduces relapses and recurrences, and
consequently overcomes the reduction in QALYs
resulting from depression, this gain is apparently
not sufficient to offset the lower utility values in
treatment in responders.
The results of any modeling exercise need to be
treated with some degree of caution. It is worth-
while to keep in mind that the purpose of pharma-
coeconomic studies is to inform or aid in decision
making and not to usurp the relationship between
patient and physician or to interfere with the phy-
sician’s treatment decision based on his assessment
of the patient’s clinical status. This model adheres
to this tenet. Analytical-decision techniques, upon
which our Markov model is based, have several
weaknesses. Among them is the fact that the re-
sults of our literature review do not necessarily
represent actual clinical practice, since much of
the literature examined was based on data from
clinical trials. Data from clinical trials does not
necessarily have a high degree of external validity
because the results are often contingent upon pro-
tocol adherence, which is not representative of
treatment modalities outside the trial setting.
We analyzed lost productivity in our model.
The use of lost productivity in pharmacoeconomic
studies remains controversial. The Australian guide-
lines did not see them as central to pharmacoeco-
nomic analyses and recommended that they be re-
ported only in rare instances [70]. The more recent
Canadian guidelines seem willing to accept esti-
mates of lost productivity from the societal per-
spective as long as the source of the cost data is
documented and a sensitivity analysis has been
performed [71]. The recent Dutch pharmacoeco-
nomic research guidelines also recommend the in-
clusion of costs resulting from lost productivity
and working days lost [53]. Based on the so-called
friction method, the period over which the pro-
duction losses are calculated is limited to the fric-
tion period, which is the period between the start
of absence and the actual moment of replacement.
This period is currently estimated at 3 months on
 
Table 8
 
Sensitivity analysis of base case—continuation treatment
 
Sensitivity analysis Range ICR: Medical costs ICR: Total costs
Relapse 0.0160 Termination dominant Termination dominant
0.04 Termination dominant Termination dominant
Response hospitalization 0.518 Termination dominant Termination dominant
0.643 Termination dominant Termination dominant
Per diem (NLG) 260 Termination dominant Termination dominant
318 Termination dominant Termination dominant
DTC:TCA (NLG) 0.94 Termination dominant Termination dominant
No discounting 0% Termination dominant Termination dominant
 
Discounting at 4%. ICR, incremental cost-effectiveness ratio; DTC, daily treatment cost; TCA, tricyclic antidepressant.
 
Table 9
 
Sensitivity analysis of scenario—maintenance treatment
 
Sensitivity analysis Range ICR: Medical costs ICR: Total costs
Relapse 0.0160 Prolongation dominant Prolongation dominant
0.04 Termination dominant Termination dominant
Recurrence 0.036 Prolongation dominant Prolongation dominant
0.04 Prolongation dominant Prolongation dominant
Response hospitalization 0.518 Prolongation dominant Prolongation dominant
0.643 Prolongation dominant Prolongation dominant
Per diem (NLG) 260 Prolongation dominant Prolongation dominant
318 Prolongation dominant Prolongation dominant
DTC:TCA (NLG) 0.94 Prolongation dominant Prolongation dominant
No discounting 0% Prolongation dominant Prolongation dominant
 
Discounting at 4%. ICR, incremental cost-effectiveness ratio; DTC, daily treatment cost; TCA, tricyclic antidepressant.
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average. We used the Friction Cost Method to
avoid any overestimation of the impact of costs of
lost productivity caused by prolonged treatment.
We only included indirect costs due to lost pro-
ductivity. The inclusion of all indirect costs would
make results less credible. There is no consensus,
yet, among scientists on how to deal with time
spent on unpaid activities and time spent by care-
givers. In addition, the health care decision maker
tends to be interested only in medical costs, while
general policy makers may also be interested in in-
direct costs caused by productivity losses. There-
fore, the current analysis can be considered an un-
derestimation of the true benefits to society of
prolongation of antidepressant medication.
The results of this study confirm that the use of
maintenance therapy with SSRIs in the treatment
of depressive disorders is justified. A number of
studies, which vary from modeling studies to ret-
rospective database analyses, have all shown that
the higher drug costs of maintenance treatment
with SSRIs are offset by savings in other medical
costs, mainly hospitalization. In a study by Hatzi-
andreu et al. [27], a model was constructed that
followed two cohorts of 35-year-old women at
high risk for recurrent depression over their life-
times. The authors concluded that long-term main-
tenance treatment with sertraline appears to be clini-
cally and economically justified for patients at
high risk of recurrent depression [65], which cor-
responds with the findings of studies by Boyer
[72] and Kamlet [29]. In addition to the study by
Nuijten et al. [59], using a Markov process analy-
sis showed that total costs associated with a 1-year
period of maintenance therapy for depression in
Germany were 33% lower with the SSRI citalo-
pram than with TCAs, and again, relapse rates
had a large impact on the model characteristics.
However, most of those studies compared initial
treatment with SSRI and initial treatment with TCA,
 
Table 10
 
Compliance with SSRIs for base case of 9 months
 
Outcome
Costs (NLG) Time without depression QALY
Direct costs Cost of lost productivity Total costs % Months Years
Compliance 
 

 
 20%
Prolongation 634 788 1422 88.5 7.96 0.61
Termination 474 909 1383 86.4 7.78 0.61
Difference 161
 

 
121 39 2.1 0.19 0.00
ICR (Cost/month) 854 210
ICR (Cost/QALY) TD* TD
Compliance 
 

 
 80%*
Prolongation 1116 425 1541 94.8 8.53 0.60
Termination 474 909 1383 86.4 7.78 0.61
Difference 642
 

 
484 158 8.4 0.75
 

 
0.01
ICR (Cost/month) 854 210
ICR (Cost/QALY) TD TD
 
*Discounting at 4%. QALY, quality-adjusted life years; ICR, incremental cost-effectiveness ratio; TD, termination dominant.
 
Table 11
 
Compliance with SSRIs for maintenance of 12 months
 
Outcome
Costs (NLG) Time without depression QALY
Direct costs Cost of lost productivity Total costs % Months Years
Compliance 
 

 
 20%
Prolongation 3670 1227 4789 84.0 17.64 1.27
Termination 4681 4282 8963 82.9 14.92 1.31
Difference
 

 
1011
 

 
3055
 

 
4175 15.1 2.72
 

 
0.04
ICR (Cost/month) PD* PD
ICR (Cost/QALY) PD PD
Compliance 
 

 
 80%*
Prolongation 3277 664 3506 91.1 19.13 1.27
Termination 4681 4282 8963 82.9 14.92 1.31
Difference
 

 
1404
 

 
3618
 

 
5457 23.3 4.21
 

 
0.04
ICR (Cost/month) PD  PD
ICR (Cost/QALY) PD  PD
 
*Discounting at 4%. QALY, quality-adjusted life years; ICR, incremental cost-effectiveness ratio; PD, prolongation dominant.
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assuming continuation of SSRI and discontinua-
tion of TCA; hence they compared both type of drug
and duration of treatment. In our study we compared
prolongation of treatment to termination in pa-
tients who responded to an initial treatment with
SSRIs. This approach allowed us to evaluate the cost-
effectiveness of a treatment prolongation alone,
which is a sounder scientific design.
The increased patient tolerability of SSRIs clearly
makes them ideal agents for the long-term mainte-
nance phase of treatment [20]. Nevertheless, a study
by Quik and Kleintjens [73] showed that Dutch
patients in the GP setting do not receive sufficiently
long antidepressant therapy, including with SSRIs.
Another Dutch study by De Waal [44], which
showed that all patients using SSRIs received the
minimal effective dosage, may indicate that the in-
sufficient treatment period may not be a result of
the unfavorable safety profile of SSRIs, but of
other factors. For example, physicians may not al-
ways communicate the importance of continuing
antidepressant treatment in symptom-free patients,
who may consider themselves as completely recov-
ered. Hence, practice guidelines based on research
may not be applicable to real-world practice. Im-
portant feasibility issues such as constraints faced
by practitioners, concerns of patients, and the lim-
itations of the health care system need to be con-
sidered. In a supplementary analysis we showed that
compliance is a main feasibility constraint from a
health-economic perspective. The validity of prac-
tice guidelines ranks as the most critical attribute,
even though it may be the hardest to define and
measure. Conceptually, practice guidelines are valid
if they lead to the health and cost outcomes pro-
jected for them while all other parameters remain
equal. A prospective collection of health-economic
data and utilities in a naturalistic setting may vali-
date the projected health-economic outcomes of
our model and identify and assess the critical real-
life issues such as noncompliance.
 
Conclusion
 
The results of this cost-effectiveness study show
that clinical guidelines for continuation treatment
are not justified from a health-economic perspec-
tive. A scenario analysis showed that extension of
the continuation treatment to maintenance treat-
ment might substantially increase the cost-effec-
tiveness of the treatment guideline. The increased
effectiveness and the reduction of total costs offset
the higher medication costs for antidepressant ther-
 
apy. Sensitivity analyses confirmed the robustness
of these findings.
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